Advancing Evidence Generation in Small, Diverse, Understudied Population
- 31 October 2026
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
Abstract
Many clinically important patient groups remain systematically underrepresented in drug development. Among these are patients with severe or time‐varying organ dysfunction, pregnant and lactating women, children with ultrarare diseases, and people from socioeconomically or geographically underserved communities. Traditional clinical trials frequently exclude such groups. Little direct evidence is generated as a result, leaving benefit–risk and dosing decisions uncertain and trial findings poorly generalizable to the patients who will ultimately receive the drug. No single method closes this gap. This review argues that progress instead comes from integration, combining model‐informed drug development, registries and real‐world data, external and virtual controls, Bayesian borrowing, and patient‐centric trial designs into a coherent totality‐of‐evidence package. These tools are maturing from a role that supplements clinical data toward one that can, in defined settings, partially replace it. The appropriate approach may differ by population. For example, (1) mechanistic modeling and exposure prediction for organ replacement therapy/changing organ function or from the altered maternal–fetal–infant physiology that makes prospective studies impractical; (2) registry‐based external controls and natural history data where patients are too few to randomize; and (3) decentralized, partnership‐driven designs to reach populations that structural barriers would otherwise exclude. Three case studies (dose justification across hepatic and renal impairment, evidence generation in women of childbearing potential with chronic autoimmune disease, and a registry‐anchored ultrarare pediatric program) illustrated these approaches. Mapped to evolving regulatory frameworks, these strategies can deliver population‐appropriate dosing at approval rather than through postmarketing commitments, accelerating equitable access to safe and effective therapies.Keywords
This publication has 76 references indexed in Scilit:
- Role of Clinical Pharmacology in Diversity and Inclusion in Global Drug Development: Current Practices and Industry Perspectives: White PaperClinical Pharmacology & Therapeutics, 2024
- A Review of the Evolving Landscape of Inclusive Research and Improved Clinical Trial AccessClinical Pharmacology & Therapeutics, 2023
- Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing RecommendationsClinical Pharmacology & Therapeutics, 2021
- Physiologically‐Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry PerspectiveClinical Pharmacology & Therapeutics, 2020
- Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus StatementClinical Pharmacology & Therapeutics, 2020
- Discordance Between Child‐Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology CompoundsThe Journal of Clinical Pharmacology, 2020
- Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient PopulationsClinical Pharmacology & Therapeutics, 2018
- Are We Ready to Include Organ‐Impaired Patients in Oncology Trials? A Clinical Pharmacology Perspective on Recent RecommendationsThe Journal of Clinical Pharmacology, 2018
- The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and AcademiaHuman Mutation, 2013
- Late infantile neuronal ceroid lipofuscinosis: Quantitative description of the clinical course in patients with CLN2 mutationsAmerican Journal of Medical Genetics, 2002